Medical News / From ASH Meeting 2020: Anticoagulant, Antiplatelet Use Not Linked to Better COVID-19 Outcomes

Despite significant prevalence of coagulopathy risk in patients with coronavirus 2019 (COVID-19), anticoagulant or antiplatelet therapy may not reduce patients’ risk of severe outcomes. In a new retrospective cohort assessment of patients with COVID-19 treated at Kaiser Permanente Northern California (KPNC) during the early months of the pandemic, investigators observed that neither antiplatelet nor anticoagulant therapy was associated with adjusted reduction of outcomes including venous thromboembolism (VTE). Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Children with chronic medical conditions like sickle cell disease may spend a significant amount of time ... read more
Findings from a new study suggest there may be inherent educational biases in neurocognitive screening measures ... read more
The first reported phase 3 trial data for hemophilia B treated with a gene therapy show ... read more
Children with sickle cell anemia face an increased risk of intracranial and extracranial arteriopathy from as ... read more